Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906371 · ClinicalTrials.gov registry record · Phase 1
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
A Phase 1 study of Lymphoblastic Leukemia, Acute, Childhood, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02906371 is a Phase 1 study of Lymphoblastic Leukemia, Acute, Childhood that has completed, run by University of Pennsylvania. The registered enrollment target is 80 participants, above the 26-participant average among 4 other Lymphoblastic Leukemia, Acute, Childhood trials with a reported enrollment target (208% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02906371, a Phase 1 study of Lymphoblastic Leukemia, Acute, Childhood, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated cytokine release syndrome safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high versus low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
Conditions Studied
Interventions
- DRUG Tocilizumab
- BIOLOGICAL CART 19
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906371
The ClinicalTrials.gov registry entry for NCT02906371 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 26-participant average among 4 other Lymphoblastic Leukemia, Acute, Childhood trials with a reported enrollment target (208% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoblastic Leukemia, Acute, Childhood appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.
NCT02906371 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02906371 about?
NCT02906371 is a clinical study titled "Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome". This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated cytokine release syndrome safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high versus...
What is the current status of trial NCT02906371?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2016-08. Estimated completion is 2021-06-30.
What conditions does trial NCT02906371 study?
This clinical trial studies the following conditions: Lymphoblastic Leukemia, Acute, Childhood.
What interventions are being tested in trial NCT02906371?
The interventions under investigation include: Tocilizumab (DRUG), CART 19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02906371?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02906371 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoblastic Leukemia, Acute, Childhood
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 1
-
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
COMPLETED · Phase 1
-
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.